Understanding the market for pharmacogenomic testing

**药物基因组学的实施是最具创新性和令人兴奋的处方药方法，因为控制试验被开发来确定药物的安全性和有效性**。通过对病人的DNA进行分析，现在医生有可能做出量身定制的处方选择，最大限度地在第一时间选择正确的药物，并以最有效的剂量。这就是药物基因组学（PGx）。** PGx的主要好处预计是：**1)减少从药物中获得治疗效果的时间，2)减少多种药物使用，以及3)避免药物不良反应，目前NHS每年花费约5亿英镑来管理和治疗因此住院的患者。虽然公共卫生系统正在努力解决有关PGx广泛实施的问题，预计需要几年时间才能解决，但我们已经有了一种解决方案，可以让个人订购自己的测试。然而，由于这是一项相对较少人了解的新技术，从患者的角度来看，很少有人知道实施的障碍，也很少有人知道他们的全科医生或处方药剂师需要如何支持使用我们提供的信息。虽然许多药物已经带有基因指南供医生遵循，但他们通常无法获得患者的遗传信息，因此在开处方时无法考虑这一重要因素。我们希望加快PGx的私人实施，以便能够更快、更顺畅地及时应用于公共卫生领域，并建立对该技术的信任。* *我们的建议结构进行市场研究侧重于以下组:* * 1)私人自费patients2)一般practitioners3药剂师* *我们将进行定量和定性的分析,了解目标市场:* * 1)人们的看法PGx are2)的主要障碍/担忧使用PGx(以及我们如何建立信任的技术)3)病人最有可能如何访问PGx(通过医生/ HCP或直接)4)非常敏感产品**该项目将分为3个部分：**1)大规模定量研究；2)小规模定性分析，涉及一小群患者；3)小规模定性分析，涉及一小群医生、药剂师和hcps。这项研究将使我们能够通过更好的患者定位，加快PGx的实施。

**The implementation of pharmacogenomics is the most innovative and exciting approach to prescription medicine since controlled trials were developed to determine a drug's safety and efficacy**. By profiling a patient's DNA, it is now possible for doctors to make tailored prescription choices, maximising the chances of choosing the right medicine, first time, and at the most effective dose. This is pharmacogenomics (or PGx).**The main benefits of PGx are expected to be:**1) reduced time to therapeutic benefit from a drug,2) reduction in polypharmacy, and3) the avoidance of adverse drug reactions, which currently cost the NHS an estimated £500m a year to manage and treat those hospitalised as a result.While public health systems are grappling with the issues around widespread implementation of PGx, which are expected to take several years to resolve, we have a solution which is already on the market enabling private individuals to order their own test. However, as this is a new technology which relatively few people are yet aware of, little is known about the barriers to implementation from a patient's perspective or how their GP or prescribing pharmacist will need to be supported to use the information we provide. Whilst many drugs already carry genetic guidance for doctors to follow, they do not routinely have access to the patient's genetic information, so are unable to consider this important factor when prescribing.We want to speed up the private implementation of PGx to enable a faster and smoother path to public health adoption in time and build trust in the technology.**Our proposal is to carry out structured market research focusing on the following groups:**1) Private self-paying patients2) General practitioners3) Pharmacists**We will carry out quantitive and qualitative analysis of the target market to understand:**1) what people's perceptions of PGx are2) what the main barriers/concerns are for the use of PGx (and how do we build trust in the technology)3) how patients are most likely to access PGx (via doctor/HCP or direct)4) how sensitive product pricing is and what level maximises uptake**The project will be divided into 3 parts:**1) large scale quantitive study2) smaller scale qualitative analysis involving a small group of patients3) smaller scale qualitative analysis involving a small group of doctors, pharmacists and HCPsThis study will enable us to speed up implementation of PGx through better patient targeting.